In yesterday’s Wall Street session, Syros Pharmaceuticals Inc (NASDAQ:SYRS) shares traded at $0.36, down -86.85% from the previous session.
SYRS stock price is now -82.42% away from the 50-day moving average and -92.12% away from the 200-day moving average. The market capitalization of the company currently stands at $9.63M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target enhanced from $11 to $15, H.C. Wainwright Upgraded its rating from Neutral to Buy for Syros Pharmaceuticals Inc (NASDAQ: SYRS). On September 22, 2020, Alliance Global Partners recently initiated its ‘Buy’ rating on the stock quoting a target price of $18, while ‘Wedbush’ rates the stock as ‘Neutral’
In other news, Chee Conley, President & CEO bought 50,000 shares of the company’s stock on Sep 11 ’24. The stock was bought for $85,420 at an average price of $1.71. Upon completion of the transaction, the President & CEO now directly owns 122,504 shares in the company, valued at $44101.44. An SEC document containing details of the transaction can be found on the SEC’s website. On Sep 12 ’24, Chief Financial Officer Haas Jason bought 45,344 shares of the business’s stock. A total of $76,006 was incurred on buying the stock at an average price of $1.68. This leaves the insider owning 124,552 shares of the company worth $44838.72. A total of 26.57% of the company’s stock is owned by insiders.
During the past 12 months, Syros Pharmaceuticals Inc has had a low of $1.43 and a high of $8.17. The fifty day moving average price for SYRS is $2.0657 and a two-hundred day moving average price translates $4.590275 for the stock.
The latest earnings results from Syros Pharmaceuticals Inc (NASDAQ: SYRS) was released for 2024-09-30. The net profit margin was -25340.67% and return on equity was -776.96% for SYRS.
